Peripheral artery disease: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• BTK 9
• GLP-1 1
• SGLT2 1
• PCSK9 1
• APOE 0
• HIF-1 0
• PPAR 0
• VEGF 0
• AKT 0
• ERK 0
• ABL1 0
• CCR5 0
• IL-17 1
• IL-6 0
• KEAP1 0
• NLRP3 0
• NRF2 1
• PTEN 0
• RUNX1 0
• STAT3 0
• TNF 0
• TP53 0
• TREM2 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NHLBI · R44

  Development and Chronic Preclinical Assessment of a Flexible Endovascular Scaffold for Treating Stenosis in the Femoropopliteal Arterial Segments

  Ev2 Technologies, Inc.· Pittsburgh, Egyesült Államok· 918 166 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NHLBI · R01

  Immune-mediated mechanisms of VEGF-A165 alternative splicing in angiogenesis in the context of Advanced Aging

  Ocean State Research Institute, Inc.· Providence, Egyesült Államok· 514 340 USD awarded in fiscal year 2026· until 2031. máj.

• NIH NHLBI · R43

  Development of combined U-turn catheter and self-anchoring sheath system for turning direction of established percutaneous vascular access

  Upstream Access, Inc· Camden, Egyesült Államok· 320 893 USD awarded in fiscal year 2026· until 2027. márc.

• NIH NIA · R21

  Urolithin A to Improve Mitochondria and Mobility in Peripheral Artery Disease: Urolithin for PAD Trial

  Northwestern University· Chicago, Egyesült Államok· 214 006 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIBIB · F32

  Bedside oximetry system for minimally invasive quantitative measurement and monitoring of tissue oxygenation.

  Dartmouth College· Hanover, Egyesült Államok· 76 780 USD awarded in fiscal year 2026· until 2027. szept.

• European Commission (Horizon Europe) · HORIZON-ERC

  From niche to function: how endothelial cell interactions orchestrate muscle function in health and disease (InterECt)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Svájc· EU contribution 2 498 888 EUR· until 2032. ápr.

• European Commission (Horizon Europe) · HORIZON-ERC

  Single cEll guided polygeniC Risk prEdicTion of ASCVD (SECRET)

  Ita-Suomen Yliopisto· Kuopio, Finnország· EU contribution 2 000 000 EUR· until 2029. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  MultiomIcs based Risk stratification of Atherosclerotic CardiovascuLar disEase (MIRACLE)

  Ita-Suomen Yliopisto· Kuopio, Finnország· EU contribution 4 599 866 EUR· until 2027. szept.· 6 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  PERSONALIZED REHABILITATION VIA NOVEL AI PATIENT STRATIFICATION STRATEGIES (PREPARE)

  Aristotelio Panepistimio Thessalonikis· Thessaloniki, Görögország· EU contribution 5 774 113 EUR· until 2027. máj.· 9 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  DEVELOPING TRUSTWORTHY ARTIFICIAL INTELLIGENCE (AI)-DRIVEN TOOLS TO PREDICT VASCULAR DISEASE RISK AND PROGRESSION (VASCUL-AID)

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 5 969 125 EUR· until 2029. ápr.· 10 countries

10 of 216 running projects, newest first. Listed amounts together: 125,3 M USD + 20,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 1
• Mendelian Randomization Analysis 18
• CRISPR-Cas Systems 1
• Gene Expression Profiling 5
• Proteomics 9
• Metabolomics 6
• Flow Cytometry 1
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 9
• Machine Learning 18
• Deep Learning 5
• Cohort Studies 53
• Genome-Wide Association Study 22

• Residual lipid-related proteomic and metabolomic signatures associated with major adverse cardiovascular events after revascularization in peripheral artery disease.

  BMC Cardiovasc Disord, 2026. szept.

• Mitochondrial Omics in Macrophage Foam Cell Formation and Atherosclerosis.

  Proteomics, 2026. aug.

• Proteomic insights of peripheral artery disease across the glycemic spectrum: a prospective cohort study.

  Metabolism, 2026. aug.

• Shared proteomic landscape between arteriosclerosis and cardiovascular endpoints: a Mendelian randomization and observational study integrating AlphaFold3 for structural prediction.

  Cardiovasc Res, 2026. jún.

• Identification of multi-omic pleiotropy factors for peripheral artery disease.

  Hum Mol Genet, 2026. máj.

• Blood pressure, proteomic vascular ageing, and incident cardiovascular disease.

  Eur J Prev Cardiol, 2026. máj.

• Enhanced Prediction of Peripheral Artery Disease Using Plasma Proteomics Among Individuals Without Diabetes.

  J Am Heart Assoc, 2026. máj.

• Proteomics-derived organ-specific aging clusters predict macrovascular and microvascular complications in diabetes.

  Cardiovasc Diabetol, 2026. febr.

• Proteomic signature of metabolic dysfunction-associated steatotic liver disease and risk of atherosclerotic cardiovascular disease.

  Cardiovasc Diabetol, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.